» Articles » PMID: 12953019

Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Elevation

Overview
Journal Hypertension
Date 2003 Sep 4
PMID 12953019
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

It has been reported that hypertension and obesity often coexist with hyperuricemia. To clarify the relations between serum uric acid, plasma norepinephrine, and insulin or leptin levels in subjects with weight gain-induced blood pressure elevation, we conducted the present longitudinal study. In 433 young, nonobese, normotensive men, body mass index, blood pressure, and levels of serum uric acid, fasting plasma norepinephrine, insulin, and leptin were measured every year for 5 years. Subjects were stratified by significant weight gain and/or blood pressure elevation (>10% in body mass index or mean blood pressure) for 5 years. At entry, blood pressure, uric acid, and norepinephrine values in subjects with blood pressure elevation were greater than in those without it, although body mass index, insulin, and leptin were similar. At entry, body mass index, blood pressure, uric acid, and norepinephrine in subjects with weight gain were greater than in those without weight gain. The increases in body mass index, mean blood pressure, uric acid, norepinephrine, insulin, and leptin for 5 years were greater in subjects with blood pressure elevation and/or weight gain than in subjects without, and those increases were greatest in subjects with weight gain whose blood pressure was elevated. By multiple regression analysis, basal mean blood pressure, norepinephrine, and uric acid were significant determinant factors of changes in mean blood pressure over 5 years, and basal body mass index, norepinephrine, and uric acid were significant determinant factors of changes in body mass index. These results demonstrate that serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.

Citing Articles

Childhood body size, adulthood adiposity, underlying mechanisms, and risk of incident hypertension: a prospective cohort study of 180,527 participants.

Ma S, Liu X, Lin R, Yao Y, Zhao M, Yu Y BMC Med. 2025; 23(1):47.

PMID: 39871294 PMC: 11773732. DOI: 10.1186/s12916-025-03884-8.


One-Year Risk Prediction of Elevated Serum Uric Acid Levels in Older Adults: A Longitudinal Cohort Study.

Zhang D, Xu X, Ye Z, Zhang Z, Xiao J Clin Interv Aging. 2024; 19:1951-1964.

PMID: 39605933 PMC: 11600923. DOI: 10.2147/CIA.S476806.


Interaction of serum uric acid with overweight on hypertension: findings from the China Health and Nutrition Survey.

Wang H, Fan J BMC Cardiovasc Disord. 2024; 24(1):614.

PMID: 39487411 PMC: 11529304. DOI: 10.1186/s12872-024-04287-y.


Impact of hyperuricemia on CKD risk beyond genetic predisposition in a population-based cohort study.

Kim Y, Jo J, Ji Y, Bae E, Lee K, Paek J Sci Rep. 2024; 14(1):18466.

PMID: 39122851 PMC: 11316130. DOI: 10.1038/s41598-024-69420-5.


Effects of Febuxostat Therapy on Circulating Adipokine Profiles in Patients with Overweight or Obesity and Asymptomatic Hyperuricemia: A Randomized Controlled Study.

Dong M, Cui Z, Liu Y, Bu Y, An K, Mao L Obes Facts. 2024; 17(5):524-534.

PMID: 39116844 PMC: 11458164. DOI: 10.1159/000540701.